866-997-4948(US-Canada Toll Free)

Vulvovaginal Candidiasis - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Diseases & Conditions

No. of Pages : 63 Pages

Vulvovaginal Candidiasis - Pipeline Review, H1 2014

Summary

Global Markets Directs, Vulvovaginal Candidiasis - Pipeline Review, H1 2014, provides an overview of the Vulvovaginal Candidiasiss therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vulvovaginal Candidiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vulvovaginal Candidiasis and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Vulvovaginal Candidiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Vulvovaginal Candidiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vulvovaginal Candidiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Vulvovaginal Candidiasis Overview 7
Therapeutics Development 8
Pipeline Products for Vulvovaginal Candidiasis - Overview 8
Pipeline Products for Vulvovaginal Candidiasis - Comparative Analysis 9
Vulvovaginal Candidiasis - Therapeutics under Development by Companies 10
Vulvovaginal Candidiasis - Therapeutics under Investigation by Universities/Institutes 12
Vulvovaginal Candidiasis - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Unknown Stage Products 15
Vulvovaginal Candidiasis - Products under Development by Companies 16
Vulvovaginal Candidiasis - Products under Investigation by Universities/Institutes 17
Vulvovaginal Candidiasis - Companies Involved in Therapeutics Development 18
Actavis plc 18
Pevion Biotech AG 19
Novabiotics Ltd 20
NovaDigm Therapeutics, Inc. 21
Grupo Ferrer Internacional, S.A. 22
TheraCarb Inc. 23
Viamet Pharmaceuticals, Inc. 24
Vulvovaginal Candidiasis - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
MGCD-290 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
albaconazole - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
arasertaconazole - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NDV-3 Vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
VT-1161 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
NDV-3A Vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PEV-7 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Candiplus - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NP-377 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Vaccine for Vaginal Candidiasis - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Glycerol Monolaurate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Vulvovaginal Candidiasis - Recent Pipeline Updates 48
Vulvovaginal Candidiasis - Dormant Projects 52
Vulvovaginal Candidiasis - Discontinued Products 53
Vulvovaginal Candidiasis - Product Development Milestones 54
Featured News & Press Releases 54
Sep 26, 2013: NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis 54
Sep 24, 2013: Viamet Pharmaceuticals Expands Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 55
Sep 05, 2013: Viamet Pharmaceuticals Initiates Phase 2 Clinical Program with Novel Antifungal Agent VT-1161 55
Mar 18, 2013: MethylGene Reports Results Of Phase II Trial Of MGCD290 56
Dec 19, 2012: MethylGene Completes Enrollment In Phase II Trial Of MGCD290 56
Oct 22, 2012: Methylgene Presents Phase I Data Of Anti-fungal Drug Candidate MGCD290 At IDWeek 2012 57
Oct 10, 2012: MethylGene Provides Clinical Update On MGCD290 New Antifungal Therapeutic Program 58
Sep 11, 2012: MethylGene Presents Preclinical Data Of Antifungal Candidate MGCD290 At ICAAC 2012 58
Sep 04, 2012: MethylGene To Present MGCD290 Data At 2012 Annual Interscience Conference On Antimicrobial Agents And Chemotherapy 59
Aug 08, 2012: Ferrer Submits IND For Arasertaconazole Nitrate For Vulvovaginal Candidiasis 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Table

List of Tables
Number of Products under Development for Vulvovaginal Candidiasis, H1 2014 8
Number of Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Comparative Analysis by Unknown Stage Development, H1 2014 15
Products under Development by Companies, H1 2014 16
Products under Investigation by Universities/Institutes, H1 2014 17
Vulvovaginal Candidiasis - Pipeline by Actavis plc, H1 2014 18
Vulvovaginal Candidiasis - Pipeline by Pevion Biotech AG, H1 2014 19
Vulvovaginal Candidiasis - Pipeline by Novabiotics Ltd, H1 2014 20
Vulvovaginal Candidiasis - Pipeline by NovaDigm Therapeutics, Inc., H1 2014 21
Vulvovaginal Candidiasis - Pipeline by Grupo Ferrer Internacional, S.A., H1 2014 22
Vulvovaginal Candidiasis - Pipeline by TheraCarb Inc., H1 2014 23
Vulvovaginal Candidiasis - Pipeline by Viamet Pharmaceuticals, Inc., H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Vulvovaginal Candidiasis Therapeutics - Recent Pipeline Updates, H1 2014 48
Vulvovaginal Candidiasis - Dormant Projects, H1 2014 52
Vulvovaginal Candidiasis - Discontinued Products, H1 2014 53

List of Chart

List of Figures
Number of Products under Development for Vulvovaginal Candidiasis, H1 2014 8
Number of Products under Development for Vulvovaginal Candidiasis - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *